WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach
- PMID: 28035618
- DOI: 10.1007/s11255-016-1491-9
WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach
Abstract
Purpose: Stage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial-mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC.
Methods: Tissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin. Kaplan-Meier analysis and univariate and multivariate Cox regression analyses regarding progression-free (PFS) and cancer-specific survival (CSS) were performed.
Results: Aberrant expression of E-cadherin was recognized in 74% of patients. Kaplan-Meier analysis showed that aberrant E-cadherin expression was associated with worse 10-year PFS (62 vs. 90%, p = 0.045). In univariate analysis, aberrant E-cadherin staining, associated carcinoma in situ, grading 3 after WHO classification 1973 and infiltrative growth pattern at the invasion front were the statistically significant predictive factors for worse PFS, only infiltrative growth pattern for CSS. With regard to progression, grading 3 after WHO classification of 1973 (HR 6.49; CI 1.54-27.28, p = 0.011) and infiltrative tumor invasion pattern (HR 2.06; CI 1.10-3.86, p = 0.024) revealed as independent factors for PFS, and there was a trend also for E-cadherin expression (HR 0.45; CI 0.19-1.06; p = 0.068). Regarding CSS, infiltrative tumor growth pattern (HR 3.79; CI 1.67-8.60, p = 0.001) was the only statistically significantly independent predictive factor in multivariate Cox regression analysis.
Conclusions: Beside invasion growth pattern and WHO grading 1973 that achieved to be independent prognostic factors, there was a trend for the parameter E-cadherin expression to be of predictive value for PFS in stage pT1 hg urothelial bladder carcinoma after organ-sparing approach. Further studies on genetic level are warranted to define the distinct role of EMT in early-invasive UBC.
Keywords: E-cadherin; Epithelial–mesenchymal transition; Immunohistochemistry; Stage pT1 bladder cancer; WHO grading classifications.
Similar articles
-
Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.World J Urol. 2016 May;34(5):709-16. doi: 10.1007/s00345-015-1690-5. Epub 2015 Sep 22. World J Urol. 2016. PMID: 26394624
-
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.J Urol. 2001 May;165(5):1473-9. J Urol. 2001. PMID: 11342899
-
Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.Eur Urol. 2014 Jan;65(1):218-26. doi: 10.1016/j.eururo.2012.05.033. Epub 2012 May 19. Eur Urol. 2014. PMID: 22633802
-
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.World J Urol. 2020 Jun;38(6):1437-1449. doi: 10.1007/s00345-019-02936-y. Epub 2019 Sep 6. World J Urol. 2020. PMID: 31493109 Free PMC article.
-
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging.Virchows Arch. 2020 Jul;477(1):3-16. doi: 10.1007/s00428-020-02808-6. Epub 2020 Apr 15. Virchows Arch. 2020. PMID: 32296929 Review.
Cited by
-
Relevance of the Immunohistochemical Expression of p53 and E-cadherin in the Grading of Urothelial Carcinoma: A Single-Center Cross-Sectional Observational Study.Cureus. 2024 Oct 22;16(10):e72132. doi: 10.7759/cureus.72132. eCollection 2024 Oct. Cureus. 2024. PMID: 39575056 Free PMC article.
-
Non-muscle invasive bladder cancer biomarkers beyond morphology.Front Oncol. 2022 Aug 3;12:947446. doi: 10.3389/fonc.2022.947446. eCollection 2022. Front Oncol. 2022. PMID: 35992775 Free PMC article. Review.
-
Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence.Eur J Histochem. 2020 Mar 26;64(2):3098. doi: 10.4081/ejh.2020.3098. Eur J Histochem. 2020. PMID: 32214283 Free PMC article.
-
EMT and cancer: what clinicians should know.Nat Rev Clin Oncol. 2025 Jul 22. doi: 10.1038/s41571-025-01058-2. Online ahead of print. Nat Rev Clin Oncol. 2025. PMID: 40696171 Review.
-
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study.Investig Clin Urol. 2024 May;65(3):248-255. doi: 10.4111/icu.20230313. Investig Clin Urol. 2024. PMID: 38714515 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical